Noxopharm Limited
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Noxopharm Limited (NOXOF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.257x
Based on the latest financial reports, Noxopharm Limited (NOXOF) has a cash flow conversion efficiency ratio of -0.257x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Million) by net assets ($5.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Noxopharm Limited - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Noxopharm Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Noxopharm Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Noxopharm Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Irving Resources Inc
OTCQX:IRVRF
|
-0.005x |
|
Denali Capital Acquisition Corp. Class A Ordinary Shares
NASDAQ:DECA
|
0.008x |
|
Connection Technology Systems
TWO:3672
|
-0.056x |
|
SHAPE ROBOTICS A/S DK-10
F:50O
|
N/A |
|
Express Transindo Utama Tbk
JK:TAXI
|
-0.055x |
|
Fine Metal Technologies Public Company Limited
BK:FMT
|
-0.153x |
|
418620
KQ:418620
|
-0.218x |
|
GSD Technologies Co. Ltd
TW:6641
|
0.004x |
Annual Cash Flow Conversion Efficiency for Noxopharm Limited (2016–2024)
The table below shows the annual cash flow conversion efficiency of Noxopharm Limited from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $5.50 Million | $-684.31K | -0.125x | +89.68% |
| 2023-06-30 | $9.07 Million | $-10.95 Million | -1.206x | -111.87% |
| 2022-06-30 | $24.12 Million | $-13.73 Million | -0.569x | -162.35% |
| 2021-06-30 | $40.78 Million | $-8.85 Million | -0.217x | +74.91% |
| 2020-06-30 | $12.87 Million | $-11.14 Million | -0.865x | -112.84% |
| 2019-06-30 | $-1.45 Million | $-9.78 Million | 6.740x | +853.61% |
| 2018-06-30 | $10.15 Million | $-9.08 Million | -0.894x | +24.37% |
| 2017-06-30 | $2.47 Million | $-2.92 Million | -1.183x | +94.43% |
| 2016-06-30 | $25.88K | $-549.72K | -21.245x | -- |